Abstract |
Intrasalivary gland injection of botulinum toxin type A is known to treat sialorrhea effectively in children with cerebral palsy. However, oral health may be compromised with escalating dose. In this randomized, double-blind, and placebo-controlled pilot trial, the authors aim to determine the therapeutic effect of low-dose, ultrasonography-controlled botulinum toxin type A injection to bilateral parotid and submandibular glands on oral health in the management of sialorrhea. Twenty children diagnosed with cerebral palsy were randomly assigned to 2 groups. The treatment group received botulinum toxin type A injections, whereas the control received normal saline in the same locations. The authors evaluated subjective drooling scales, salivary flow rate, and oral health (salivary compositions and cariogenic bacterial counts). A significant decrease was found in salivary flow rate at the 1- and 3-month follow-up in the botulinum toxin-treated group. The authors suggest that current protocol can effectively manage sialorrhea while maintaining oral health.
|
Authors | Katie Pei-Hsuan Wu, Jyh-Yuh Ke, Chung-Yao Chen, Chia-Ling Chen, Ming-Yen Chou, Yu-Cheng Pei |
Journal | Journal of child neurology
(J Child Neurol)
Vol. 26
Issue 7
Pg. 838-43
(Jul 2011)
ISSN: 1708-8283 [Electronic] United States |
PMID | 21551374
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Neurotoxins
- Placebos
- Botulinum Toxins, Type A
|
Topics |
- Adolescent
- Botulinum Toxins, Type A
(administration & dosage, adverse effects)
- Cerebral Palsy
(complications)
- Child
- Child, Preschool
- Double-Blind Method
- Female
- Humans
- Male
- Neurotoxins
(administration & dosage, adverse effects)
- Pilot Projects
- Placebos
- Saliva
(chemistry, drug effects, metabolism)
- Sialorrhea
(drug therapy, etiology, physiopathology)
|